CEO
UB-Therapeutics, Israel
Dr. Dima Ghannam Shahbari is a highly accomplished researcher in the field of oncology, with a strong background in R&D spanning over 10 years. She holds a bachelor's degree in biology from Tel Aviv University, followed by a master's and Ph.D. in medical sciences from the Technion, where she participated in the direct excellence track.
During her academic journey, Dr. Ghannam Shahbari excelled in her studies and was honored with a faculty excellence scholarship. Her research primarily focused on elucidating the various mechanisms that drive epithelial ovarian cancer proliferation, as well as exploring potential therapeutic interventions. Her groundbreaking findings were published in the esteemed scientific journal Oncogene, contributing valuable insights to the field.
Dr. Dima Ghannam Shahbari currently holds the position of CEO at a newly established company named "Ubi Therapeutics," located within the NGT (New Generation Technology) incubator. Under her leadership, Ubi Therapeutics is dedicated to revolutionizing the treatment of Multiple myeloma (MM), a complex hematological malignancy. The company's pioneering approach involves the development of a novel proteasome degradation inhibitor drug candidate that operates through a distinct mode of action.
With her extensive expertise in molecular biology, deep understanding of cancer biology, and commitment to scientific excellence, Dr. Ghannam Shahbari is spearheading the efforts to address the unmet medical needs of patients suffering from Multiple myeloma. Her visionary leadership and dedication to advancing the field of oncology position Ubi Therapeutics as a frontrunner in the development of innovative therapies.
Driven by her passion for scientific discovery and her unwavering commitment to improving patient outcomes, Dr. Dima Ghannam Shahbari is making significant contributions to the field of cancer research and therapeutics. Her impressive track record and leadership qualities underscore her as a prominent figure in the scientific community, shaping the future of Multiple myeloma treatment.